- Home
- IMXI vs IMAB Comparison
IMXI vs IMAB Comparison
Compare IMXI & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMXI
- IMAB
- Stock Information
- Founded
- IMXI 1994
- IMAB 2014
- Country
- IMXI United States
- IMAB United States
- Employees
- IMXI N/A
- IMAB N/A
- Industry
- IMXI Retail: Computer Software & Peripheral Equipment
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- IMXI Technology
- IMAB Health Care
- Exchange
- IMXI Nasdaq
- IMAB Nasdaq
- Market Cap
- IMXI 414.7M
- IMAB 394.2M
- IPO Year
- IMXI N/A
- IMAB 2020
- Fundamental
- Price
- IMXI $13.95
- IMAB $4.33
- Analyst Decision
- IMXI Buy
- IMAB Strong Buy
- Analyst Count
- IMXI 5
- IMAB 6
- Target Price
- IMXI $19.60
- IMAB $7.17
- AVG Volume (30 Days)
- IMXI 320.2K
- IMAB 1.6M
- Earning Date
- IMXI 11-07-2025
- IMAB 11-02-2025
- Dividend Yield
- IMXI N/A
- IMAB N/A
- EPS Growth
- IMXI N/A
- IMAB N/A
- EPS
- IMXI 1.65
- IMAB N/A
- Revenue
- IMXI $642,149,000.00
- IMAB N/A
- Revenue This Year
- IMXI N/A
- IMAB N/A
- Revenue Next Year
- IMXI $1.87
- IMAB N/A
- P/E Ratio
- IMXI $8.51
- IMAB N/A
- Revenue Growth
- IMXI N/A
- IMAB N/A
- 52 Week Low
- IMXI $8.58
- IMAB $0.60
- 52 Week High
- IMXI $22.37
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- IMXI 46.50
- IMAB 59.09
- Support Level
- IMXI $13.91
- IMAB $3.40
- Resistance Level
- IMXI $14.28
- IMAB $4.51
- Average True Range (ATR)
- IMXI 0.12
- IMAB 0.30
- MACD
- IMXI -0.13
- IMAB 0.06
- Stochastic Oscillator
- IMXI 5.69
- IMAB 85.59
About IMXI International Money Express Inc.
International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).